Polypeptides capable of forming antigen binding structures with specificity for the Rhesus D antigens, the DNA encoding them and the process for their preparation and use
Polypeptides capable of forming antigen binding structures specific for Rhesus D antigens include the sequences indicated in the FIGS. 1 a to 16 b . The obtained polypeptides, being Fab fragments, MAY be used directly as an active ingredient in pharmaceutical and diagnostic compositions. The Fab and their DNA sequences can also be used for the preparation of complete recombinant Anti-Rhesus D antibodies. Useful in pharmaceutical and diagnostic compositions.
1. A method for treating idiopathic thrombocytopenic purpura (ITP) or mistransfusion of Rhesus incompatible blood in a subject comprising administering to the subject a pharmaceutical composition comprising a purified polypeptide capable of forming antigen binding structures with specificity for Rhesus D antigens comprising:
(a) a V H region having a sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 10, SEQ ID NO: 14, SEQ ID NO: 18, SEQ ID NO: 22, SEQ ID NO: 26, SEQ ID NO: 30, SEQ ID NO: 34, SEQ ID NO: 38, SEQ ID NO: 42, SEQ ID NO: 46, SEQ ID NO: 50, SEQ ID NO: 54, SEQ ID NO: 58 and SEQ ID NO: 62 and
(b) a V L region having a sequence selected from the group consisting of SEQ ID NO: 4, SEQ ID NO: 8, SEQ ID NO: 12, SEQ ID NO: 16, SEQ ID NO: 20, SEQ ID NO: 24, SEQ ID NO: 28, SEQ ID NO: 32, SEQ ID NO: 36, SEQ ID NO: 40, SEQ ID NO: 44, SEQ ID NO: 48, SEQ ID NO: 52, SEQ ID NO: 56, SEQ ID NO: 60, and SEQ ID NO: 64.
2. The method of claim 1 , wherein the V H region has SEQ ID NO: 58.
3. The method of claim 1 , wherein the V L region has SEQ ID NO: 60.
4. The method of claim 1 , wherein the V H region has SEQ ID NO: 58 and the V L region has SEQ ID NO: 60.
5. The method of claim 1 , wherein the polypeptide is an antigen binding Fab fragment.
6. The method of claim 1 , wherein the polypeptide is an immunoglobulin specific for a Rhesus D antigen.
7. The method of claim 6 , wherein the immunoglobulin comprises at least one defined isotype selected from the group consisting of IgG 1, IgG2, IgG3, and IgG4.
8. The method of claim 1 , wherein the composition further comprises a pharmaceutically acceptable carrier.
9. A method for protecting against haemolytic disease of the newborn (HDN) comprising administering to a Rhesus-negative woman a pharmaceutical composition comprising a purified polypeptide capable of forming antigen binding structures with specificity for Rhesus D antigens comprising:
(a) a V H region having a sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 10, SEQ ID NO: 14, SEQ ID NO: 18, SEQ ID NO: 22, SEQ ID NO: 26, SEQ ID NO: 30, SEQ ID NO: 34, SEQ ID NO: 38, SEQ ID NO: 42, SEQ ID NO: 46, SEQ ID NO: 50, SEQ ID NO: 54, SEQ ID NO: 58 and SEQ ID NO: 62 and
(b) a V L region having a sequence selected from the group consisting of SEQ ID NO: 4, SEQ ID NO: 8, SEQ ID NO: 12, SEQ ID NO: 16, SEQ ID NO: 20, SEQ ID NO: 24, SEQ ID NO: 28, SEQ ID NO: 32, SEQ ID NO: 36, SEQ ID NO: 40, SEQ ID NO: 44, SEQ ID NO: 48, SEQ ID NO: 52, SEQ ID NO: 56, SEQ ID NO: 60, and SEQ ID NO: 64.
10. The method of claim 9 , wherein the V H region has SEQ ID NO: 58.
11. The method of claim 9 , wherein the V L region has SEQ ID NO: 60.
12. The method of claim 9 , wherein the V H region has SEQ ID NO: 58 and the V L region has SEQ ID NO: 60.
13. The method of claim 9 , wherein the polypeptide is an antigen binding Fab fragment.
14. The method of claim 9 , wherein the polypeptide is an immunoglobulin specific for a Rhesus D antigen.
15. The method of claim 14 , wherein the immunoglobulin comprises at least one defined isotype selected from the group consisting of IgG1, IgG2, IgG3, and IgG4.
16. The method of claim 9 , wherein the composition further comprises a pharmaceutically acceptable carrier.
17. A method for treating a Rhesus-negative woman comprising administering to the Rhesus-negative woman a pharmaceutical composition comprising a purified polypeptide capable of forming antigen binding structures with specificity for Rhesus D antigens comprising:
(a) a V H region having a sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 10, SEQ ID NO: 14, SEQ ID NO: 18, SEQ ID NO: 22, SEQ ID NO: 26, SEQ ID NO: 30, SEQ ID NO: 34, SEQ ID NO: 38, SEQ ID NO: 42, SEQ ID NO: 46, SEQ ID NO: 50, SEQ ID NO: 54, SEQ ID NO: 58 and SEQ ID NO: 62 and
(b) a V L region having a sequence selected from the group consisting of SEQ ID NO: 4, SEQ ID NO: 8, SEQ ID NO: 12, SEQ ID NO: 16, SEQ ID NO: 20, SEQ ID NO: 24, SEQ ID NO: 28, SEQ ID NO: 32, SEQ ID NO: 36, SEQ ID NO: 40, SEQ ID NO: 44, SEQ ID NO: 48, SEQ ID NO: 52, SEQ ID NO: 56, SEQ ID NO: 60, and SEQ ID NO: 64.
18. The method of claim 17 , wherein the V H region has SEQ ID NO: 58.
19. The method of claim 17 , wherein the V L region has SEQ ID NO: 60.
20. The method of claim 17 , wherein the V H region has SEQ ID NO: 58 and the V L region has SEQ ID NO: 60.